Merck’s new Covid-19 pill analysis: Looking at what is known and unknown

What we know — and don’t know — about Merck’s new Covid-19 pill STAT looks at the unanswered questions about Merck's new Covid-19 drug, molnupiravir, and about other Covid-fighting pills in development. Matthew Herper STAT

The announcement that a pill from Merck and partner Ridgeback Biotherapeutics kept Covid patients out of the hospital made headlines and moved stocks late last week. But as is so often true when data are released by press release, there are still many questions left unanswered. ...